G-Protein Coupled Receptors (GPCR) Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 907036
出版日期 內容資訊 英文 113 Pages
商品交期: 2-3個工作天內
Back to Top
全球G蛋白偶聯受體(GPCR)市場:成長,趨勢,預測 G-Protein Coupled Receptors (GPCR) Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年06月01日內容資訊: 英文 113 Pages


第1章 簡介

第2章 調查方法

第3章 摘要整理

第4章 市場趨勢

  • 市場概要
  • 推動市場的要素
  • 阻礙市場的要素
  • 波特的五力分析

第5章 市場區隔

  • 各分析
    • 鈣水平檢測分析
    • GTP伽馬S結合分析
    • cAMP分析
    • cGMP分析
    • 受體遺傳基因分析
    • 其他
  • 各治療領域
    • 心血管系統
    • 中樞神經系統
    • 免疫系
    • 腫瘤
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第6章 競爭環境

  • 企業簡介
    • Abcam PLC
    • Becton, Dickinson and Company
    • Cisbio Bioassays
    • EMD Millipore Corporation
    • Enzo Life Sciences Inc.
    • HD Biosciences Co. Ltd
    • Promega Corporation
    • QIAGEN
    • Sigma-Aldrich Corporation (Merck KGaA)
    • Thermo Fisher Scientific Inc.

第7章 市場機會與未來趨勢

Product Code: 62547

Market Overview

The global market for G-protein coupled receptors is expected to register a CAGR of 8.7% during the forecast period By therapeutic areas, the market is anticipated to be led by oncology, over the forecast period, owing to the rising number of cases of cancer. Region-wise, the market is anticipated to grow in North America and Europe, due to the rise in the cases of obesity, in these regions. Growing prevalence of endless lifestyle issues, such as breast cancer, cardiovascular infections, and respiratory issues is prompting higher interest for novel and better treatment choices. G-protein coupled receptors (GPCRs) are exceptionally helpful in the innovative work of newer medication substances. Further, the increasing government finance in R&D activities, for instance, biosensors, orphan drug receptors, sedate targets, and high-throughput screening methods are anticipated to drive the development of the market. Additionally, the functional and structural literature on the pharmacological components of the GPCRs is demonstrating the adaptable utilities of GPCRs targets in the treatment of an expansive range of disorders. Reliance on systematic improvements in the scope of therapeutics for the management of neurobiological, irritation, torment, and other issues helps the market expansion. Further, the rising use of G-protein coupled receptors in medicate disclosure and advancement forms are required to fuel the market development. High Cost Involved in the Maintenance of GPCR Cell Lines to Impede the (G-Protein Coupled Receptors) GPCR Market.

Scope of the Report

G protein-coupled receptor (GPCR), also called seven-trans membrane receptor or heptahelical receptor, a protein located in the cell membrane that binds extracellular substances and transmits signals from these substances to an intracellular molecule called a G protein (guanine nucleotide-binding protein). GPCRs are found in the cell membranes of a wide range of organisms, including mammals, plants, microorganisms, and invertebrates. There are numerous different types of GPCRs-some 1,000 types are encoded by the human genome alone-and as a group, they respond to a diverse range of substances, including light, hormones, amines, neurotransmitters, and lipids. Some examples of GPCRs include beta-adrenergic receptors, which bind epinephrine; prostaglandin E2 receptors, which bind inflammatory substances called prostaglandins; and rhodopsin, which contains a photo reactive chemical called retinal that responds to light signals received by rod cells in the eye.

Key Market Trends

Oncology Estimated to Dominate the Global G-Protein Coupled Receptors (GPCR) Market by Therapeutic Areas

More than 700 genes are identified as the G protein-coupled receptors, which will form the largest protein superfamily in the human genome. GPCRs play a vital role in interfering a wide variety of physiological events, from sensory modulations to hormonal responses. A key recent focus for basic and clinical investigators demonstrated that signaling through GPCRs affects the various aspects of cancer biology such as invasion, migration and vascular remolding. Hence, the development of GPCR-targeted drugs will provide a novel therapeutic strategy in treating various types of cancers. As GPCR signaling is an important contributor to tumor growth and metastasis, discerning how GRKs regulate GPCR activity in cancer cells may greatly improve understanding of tumorigenesis and oncogenesis, and help develop novel anticancer therapies.

Asia-Pacific is anticipated to register a Rapid CAGR

Asia-Pacific region is expected to grow at a significant rate during the forecast period, owing to the economic development of the countries, such as China and India, along with increasing government investment in the biotechnology and biopharmaceutical sector, increasing life expectancy, rising per capita income, and unmet market needs in the region. For instance, in 2014, Janssen Research & Development, LLC and Johnson & Johnson Innovation have established an R&D collaboration with Peking University to identify agonists and antagonists for G protein-coupled receptors (GPCRs) to help develop novel CNS medicines. GPCRs interact with proteins in a cell's plasma membrane and play a role in many biological processes. An imbalance in GPCR signalling may be implicated in cognitive and other neurologic diseases. Through the collaboration, Peking University will screen candidates using their novel assay.

Competitive Landscape

Market players in Global G-Protein Coupled Receptors (GPCR) Market are focusing on the expansion of their product portfolios by adopting inorganic growth strategies such as acquisitions, mergers, and partnerships. For instance, in June 2018 Amgen's erenumab recently secured FDA approval, as the first G protein-coupled receptor-targeted antibody. Despite various challenges, several of these biologics is under manufacturing process. Key players of the Global G-Protein Coupled Receptors (GPCR) Market are Abcam PLC, Becton Dickinson, and Company, Cisbio Bioassays, EMD Millipore Corporation, Enzo Life Sciences Inc., HD Biosciences Co. Ltd, Promega Corporation, QIAGEN, Sigma-Aldrich Corporation (Merck KGaA), Thermo Fisher Scientific Inc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents


  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Applications of Cryosurgery
    • 4.2.2 Technological Advancements in Cryotherapy Equipment
    • 4.2.3 Rising Preference Towards Minimally Invasive Techniques
  • 4.3 Market Restraints
    • 4.3.1 Hazardous Effects of Cryogenic Gases
    • 4.3.2 Complexity of the cryotherapy mechanisms
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Assay Type
    • 5.1.1 Calcium Level Detection Assays
    • 5.1.2 GTP Gamma S Binding Assays
    • 5.1.3 cAMP Assays
    • 5.1.4 cGMP Assays
    • 5.1.5 Reporter Gene Assays
    • 5.1.6 Other Assays
  • 5.2 By Therapeutic Areas
    • 5.2.1 Cardiovascular System
    • 5.2.2 Central Nervous System (CNS)
    • 5.2.3 Immune System
    • 5.2.4 Oncology
    • 5.2.5 Other Therapeutic Areas
  • 5.3 Geography
    • 5.3.1 North America
      • US
      • Canada
      • Mexico
    • 5.3.2 Europe
      • Germany
      • UK
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.3.3 Asia Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • 5.3.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Abcam PLC
    • 6.1.2 Becton, Dickinson and Company
    • 6.1.3 Cisbio Bioassays
    • 6.1.4 EMD Millipore Corporation
    • 6.1.5 Enzo Life Sciences Inc.
    • 6.1.6 HD Biosciences Co. Ltd
    • 6.1.7 Promega Corporation
    • 6.1.8 QIAGEN
    • 6.1.9 Sigma-Aldrich Corporation (Merck KGaA)
    • 6.1.10 Thermo Fisher Scientific Inc.


Back to Top